Neurogen/Pfizer to collaborate on anti-obesity drug under agreement potentially worth over $60 mil.
NEUROGEN AND PFIZER WILL COLLABORATE IN ANTI-OBESITY DRUG DEVELOPMENT under an agreement in principle announced Nov. 6. Neurogen said the agreement, its third collaboration with Pfizer, "can mean as much as $60 mil." to the company, plus income from profit-sharing, manufacturing options and royalties. Pfizer will have worldwide rights to Neurogen's neuropeptide Y1 antagonist, NGD 95-1, which might suppress appetite by blocking the action of NPY, which has shown evidence of being a potent eating stimulator, the company said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth